Interferon Therapy and Prevention of Hepatocellular Carcinoma in Hepatitis C

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2012 Feb 23

PMID 22354544

Citations 2

Authors

Amit G Singal

Jorge A Marrero

Affiliations

Soon will be listed here.

Citing Articles

Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy.

Saraiya N, Yopp A, Rich N, Odewole M, Parikh N, Singal A Aliment Pharmacol Ther. 2018; 48(2):127-137.

PMID: 29851093 PMC: 6019180. DOI: 10.1111/apt.14823.

Exosomes as potent regulators of HCC malignancy and potential bio-tools in clinical application.

Qu Z, Jiang C, Wu J, Ding Y Int J Clin Exp Med. 2016; 8(10):17088-95.

PMID: 26770301 PMC: 4694201.

References

Uenishi T, Nishiguchi S, Tamori A, Yamamoto T, Shuto T, Hirohashi K . Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. Hepatol Res. 2006; 36(3):195-200. DOI: 10.1016/j.hepres.2006.07.011. View

Uenishi T, Kubo S, Hirohashi K, Tanaka H, Shuto T, Yamamoto T . Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatol Res. 2002; 24(4):404-412. DOI: 10.1016/s1386-6346(02)00147-x. View

Lai C, Lau J, Wu P, Ngan H, Chung H, Mitchell S . Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology. 1993; 17(3):389-94. View

Shiffman M, Di Bisceglie A, Lindsay K, Morishima C, Wright E, Everson G . Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004; 126(4):1015-23. DOI: 10.1053/j.gastro.2004.01.014. View

Margarit C, Escartin A, Castells L, Vargas V, Allende E, Bilbao I . Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. Liver Transpl. 2005; 11(10):1242-51. DOI: 10.1002/lt.20398. View

Singal A, Volk M, Jensen D, Di Bisceglie A, Schoenfeld P . A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2009; 8(3):280-8, 288.e1. DOI: 10.1016/j.cgh.2009.11.018. View

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote E . Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology. 2011; 140(7):1990-9. DOI: 10.1053/j.gastro.2011.03.010. View

Lok A, Everhart J, Wright E, Di Bisceglie A, Kim H, Sterling R . Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2010; 140(3):840-9. PMC: 3057272. DOI: 10.1053/j.gastro.2010.11.050. View

10.

Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S . Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003; 38(2):200-7. DOI: 10.1016/s0168-8278(02)00360-4. View

11.

McHutchison J, Everson G, Gordon S, Jacobson I, Sulkowski M, Kauffman R . Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009; 360(18):1827-38. DOI: 10.1056/NEJMoa0806104. View

12.

Volk M, Tocco R, Saini S, Lok A . Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009; 50(6):1750-5. DOI: 10.1002/hep.23220. View

13.

Poordad F, McCone Jr J, Bacon B, Bruno S, Manns M, Sulkowski M . Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364(13):1195-206. PMC: 3766849. DOI: 10.1056/NEJMoa1010494. View

14.

Singh R, Gutman M, Bucana C, Sanchez R, Llansa N, Fidler I . Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A. 1995; 92(10):4562-6. PMC: 41984. DOI: 10.1073/pnas.92.10.4562. View

15.

Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S . Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995; 346(8982):1051-5. DOI: 10.1016/s0140-6736(95)91739-x. View

16.

Miyatake H, Kobayashi Y, Iwasaki Y, Nakamura S, Ohnishi H, Kuwaki K . Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci. 2011; 57(4):1092-101. DOI: 10.1007/s10620-011-1934-1. View

17.

El-Serag H, Rudolph K . Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132(7):2557-76. DOI: 10.1053/j.gastro.2007.04.061. View

18.

Komorizono Y, Sako K, Yamasaki N, Hiwaki T, Sakurai K, Shibatou T . Outcome of patients with hepatitis C virus-related hepatocellular carcinoma occurring after interferon therapy. Anticancer Res. 2003; 22(6B):3573-8. View

19.

Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T . Influence of previous interferon therapy on recurrence after resection of hepatitis c virus-related hepatocellular carcinoma. Jpn J Cancer Res. 2001; 92(1):59-66. PMC: 5926579. DOI: 10.1111/j.1349-7006.2001.tb01048.x. View

20.

Singal A, Freeman Jr D, Anand B . Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010; 32(7):851-8. DOI: 10.1111/j.1365-2036.2010.04414.x. View